References 1. Aliyu MH, Salihu HM:
Tuberculosis and HIV disease: two decades of a dual epidemic. Wiener klinische Wochenschrift 2003,115(19–20):685–697.PubMedCrossRef 2. Iseman MD: Treatment and implications of multidrug-resistant tuberculosis for the 21st century. Chemotherapy 1999,45(Suppl 2):34–40.PubMedCrossRef 3. Global Tuberculosis Control, Epidemiology, Strategy, Financing [http://www.who.int/tb/publications/global_report/2009/pdf/full_report.pdf] 4. Batoni G, Esin S, Pardini M, Bottai D, Senesi S, Wigzell H, Campa M: Identification of distinct lymphocyte subsets responding to subcellular fractions of Mycobacterium bovis bacille calmette-Guerin (BCG). Clinical and experimental immunology 2000,119(2):270–279.PubMedCrossRef 5. Hesseling AC, Schaaf HS, Hanekom WA, www.selleckchem.com/products/sbe-b-cd.html Beyers N, Cotton MF, Gie
RP, Marais BJ, selleck screening library van Helden P, Warren RM: Danish bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 2003,37(9):1226–1233.PubMedCrossRef 6. Kaufmann SH, Baumann S, Nasser Eddine A: Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis. Int J Tuberc Lung Dis 2006,10(10):1068–1079.PubMed 7. Changhong S, Hai Z, Limei W, Jiaze A, Li X, Tingfen Z, Zhikai X, Yong Z: Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and Interleukin-3 receptor the human interleukin
2 fusion gene. Tuberculosis (Edinburgh, Scotland) 2009,89(1):54–61.CrossRef 8. Romano M, Rindi L, Korf H, Bonanni D, Adnet PY, Jurion F, Garzelli C, Huygen K: Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c). Vaccine 2008,26(48):6053–6063.PubMedCrossRef 9. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, et al.: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998,393(6685):537–544.PubMedCrossRef 10. Chakravarti DN, Fiske MJ, Fletcher LD, Zagursky RJ: Application of genomics and proteomics for identification of bacterial gene products as potential vaccine candidates. Vaccine 2000,19(6):601–612.PubMedCrossRef 11. Mustafa A: Progress towards the development of new anti-tuberculosis vaccines. In Focus on Tuberculosis Research. Edited by: LT S. New York, USA; 2005:47–76. 12. Arend SM, Geluk A, van Meijgaarden KE, van Dissel JT, Theisen M, Andersen P, Ottenhoff TH: Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis -specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infection and immunity 2000,68(6):3314–3321.PubMedCrossRef 13.